Biomarker

A neurotech company has announced an agreement with a radiopharmaceutical firm for the rights to manufacture an investigational imaging biomarker used in PET scans to assess the status of amyloid plaque in the brain.

ANAHEIM, Calif. — Better biomarkers for diagnosis and prognosis are needed for better personalized asthma care, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

The FDA has cleared a traumatic brain injury blood test for commercial availability, paving the way for its distribution to hospitals in the United States.

A Boston-area biopharmaceutical has announced additional positive biomarker data from a phase 1/2a study of a novel cancer vaccine immunotherapeutic intended to treat those with recurrent glioblastoma.

Fecal calprotectin and serum C-reactive protein biomarkers can inform disease management for patients with asymptomatic or symptomatic Crohn’s disease, according to an updated clinical practice guideline from the AGA.

Vigil Neuroscience Inc. has announced positive interim data from a phase 2 proof-of-concept clinical trial of a monoclonal antibody to treat those suffering from adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Octave Bioscience Inc. has received a $10M grant from the Michael J. Fox Foundation for Parkinson’s Research to advance a custom protein biomarker panel to clinically measure Parkinson’s disease activity and progression.

For those with multiple sclerosis, presence of elevated neurofilament light chain biomarkers was associated with symptom progression that predicted clinical disease worsening within 1 to 2 years, according to research from JAMA Neurology.

Participation in memory-based digital cognitive testing and blood-based biomarker assays for Alzheimer’s-related pathology was linked to successful enrollment into clinical trials for disease-modifying treatment, according to research.

For individuals exposed to athletic-related head contact, glial fibrillary acidic protein may help identify those who are at risk for progressive regional brain atrophy and cognitive decline, per data from Alzheimer’s Research & Therapy.